Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR3 | Q99500 | 13/20 | 0.44 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.43 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.42 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.42 |
| ▸ | CACNA1I | Q9P0X4 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6703218 | 0.85 | NPSR1 (0.39) | CACNA1GCACNA1HCACNA1I | |
| SCHEMBL6702256 | 0.84 | TRPA1 (0.49) | S1PR3PTGER4TRPA1CACNA1GCACNA1H | |
| SCHEMBL6700333 | 0.83 | S1PR3 (0.48) | S1PR3PTGER4TRPA1 | |
| SCHEMBL6700843 | 0.81 | POLB (0.44) | S1PR3PTGER4TRPA1 | |
| SCHEMBL6813950 | 0.80 | POLB (0.45) | S1PR3PTGER4TRPA1 | |
| SCHEMBL6292842 | 0.79 | PTGER4 (0.42) | S1PR3PTGER4CACNA1GCACNA1HCACNA1I | |
| SCHEMBL6701930 | 0.78 | TRPA1 (0.54) | S1PR3PTGER4TRPA1 | |
| SCHEMBL6703297 | 0.77 | MMP13 (0.42) | — | |
| SCHEMBL6682303 | 0.75 | S1PR3 (0.47) | S1PR3PTGER4TRPA1 | |
| SCHEMBL6696562 | 0.73 | PTGER4 (0.42) | S1PR3PTGER4CACNA1GCACNA1HCACNA1I |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | WILSON MICHAEL WILLIAM (US) | 2004-02-26 | — | — | US | claimed |
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | WILSON MICHAEL WILLIAM (US) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | MMP9, MMP1, MMP2 | S1PR3 1772/4885PTGER4 1609/4885TRPA1 4283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.